FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3092030598> ?p ?o ?g. }

• W3092030598 endingPage "e0240483" @default.
• W3092030598 startingPage "e0240483" @default.
• W3092030598 abstract "Introduction Prior use of direct oral anticoagulants has been associated with reduced stroke severity in patients with non-valvular atrial fibrillation (NVAF). The aim of this study was to investigate the impact of prothrombin time (PT) and activated partial thromboplastin time (aPTT) on stroke severity in patients who were receiving dabigatran or rivaroxaban at the time of stroke onset. Materials and methods We enrolled 107 patients with NVAF who developed acute ischemic stroke while on dabigatran or rivaroxaban and presented within 24 hours to nine hospitals between January 2014 and December 2018. The results of PT and aPTT assays were obtained within 24 hours of stroke onset in all patients. We analyzed PT and aPTT in relation to stroke severity and ischemic lesion volume using correlation and multivariable regression analyses. Results Of the 107 patients included, 46 (43.0%) were on dabigatran and 61 (57.0%) were on rivaroxaban. In patients with prior dabigatran use, while aPTT was inversely correlated with admission National Institutes of Health Stroke Scale (NIHSS) score (r = -0.369, p = 0.012) and ischemic lesion volume (r = -0.480, p = 0.005), there was no correlation between PT and either of these variables. Multivariable analysis confirmed the existence of a significant independent inverse relationship between aPTT and NIHSS score at admission (B, -0.201; 95% confidence interval [CI], -0.370 to -0.032; p = 0.005) and between aPTT and ischemic lesion volume (B, -0.076; 95% CI, -0.130 to -0.023; p = 0.007). In patients with prior rivaroxaban use, neither PT nor aPTT was associated with admission NIHSS score or ischemic lesion volume in the correlation and multivariable analyses. Conclusions In patients with NVAF who were receiving dabigatran, prolonged aPTT was associated with reduced stroke severity." @default.
• W3092030598 created "2020-10-15" @default.
• W3092030598 creator A5006539124 @default.
• W3092030598 creator A5006728335 @default.
• W3092030598 creator A5007021491 @default.
• W3092030598 creator A5007226118 @default.
• W3092030598 creator A5009632811 @default.
• W3092030598 creator A5012922931 @default.
• W3092030598 creator A5013808765 @default.
• W3092030598 creator A5019010535 @default.
• W3092030598 creator A5019240740 @default.
• W3092030598 creator A5021319280 @default.
• W3092030598 creator A5037543895 @default.
• W3092030598 creator A5075169325 @default.
• W3092030598 creator A5085965565 @default.
• W3092030598 creator A5087073139 @default.
• W3092030598 creator A5087998175 @default.
• W3092030598 creator A5090025679 @default.
• W3092030598 creator A5091833738 @default.
• W3092030598 date "2020-10-12" @default.
• W3092030598 modified "2023-09-30" @default.
• W3092030598 title "Effects of dabigatran and rivaroxaban on stroke severity according to the results of routine coagulation tests" @default.
• W3092030598 cites W1981340953 @default.
• W3092030598 cites W2001493305 @default.
• W3092030598 cites W2001598988 @default.
• W3092030598 cites W2023849073 @default.
• W3092030598 cites W2025657030 @default.
• W3092030598 cites W2084350674 @default.
• W3092030598 cites W2088140015 @default.
• W3092030598 cites W2104769300 @default.
• W3092030598 cites W2121695173 @default.
• W3092030598 cites W2124882231 @default.
• W3092030598 cites W2129234868 @default.
• W3092030598 cites W2129241155 @default.
• W3092030598 cites W2138595885 @default.
• W3092030598 cites W2140646485 @default.
• W3092030598 cites W2152623033 @default.
• W3092030598 cites W2156970332 @default.
• W3092030598 cites W2163853479 @default.
• W3092030598 cites W2412757059 @default.
• W3092030598 cites W2516475670 @default.
• W3092030598 cites W2557371738 @default.
• W3092030598 cites W2609687757 @default.
• W3092030598 cites W2769760280 @default.
• W3092030598 cites W2792857103 @default.
• W3092030598 cites W2799328881 @default.
• W3092030598 cites W2901705643 @default.
• W3092030598 cites W2913705661 @default.
• W3092030598 cites W2929489099 @default.
• W3092030598 cites W2946129482 @default.
• W3092030598 cites W362679014 @default.
• W3092030598 doi "https://doi.org/10.1371/journal.pone.0240483" @default.
• W3092030598 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7549802" @default.
• W3092030598 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33044991" @default.
• W3092030598 hasPublicationYear "2020" @default.
• W3092030598 type Work @default.
• W3092030598 sameAs 3092030598 @default.
• W3092030598 citedByCount "2" @default.
• W3092030598 countsByYear W30920305982023 @default.
• W3092030598 crossrefType "journal-article" @default.
• W3092030598 hasAuthorship W3092030598A5006539124 @default.
• W3092030598 hasAuthorship W3092030598A5006728335 @default.
• W3092030598 hasAuthorship W3092030598A5007021491 @default.
• W3092030598 hasAuthorship W3092030598A5007226118 @default.
• W3092030598 hasAuthorship W3092030598A5009632811 @default.
• W3092030598 hasAuthorship W3092030598A5012922931 @default.
• W3092030598 hasAuthorship W3092030598A5013808765 @default.
• W3092030598 hasAuthorship W3092030598A5019010535 @default.
• W3092030598 hasAuthorship W3092030598A5019240740 @default.
• W3092030598 hasAuthorship W3092030598A5021319280 @default.
• W3092030598 hasAuthorship W3092030598A5037543895 @default.
• W3092030598 hasAuthorship W3092030598A5075169325 @default.
• W3092030598 hasAuthorship W3092030598A5085965565 @default.
• W3092030598 hasAuthorship W3092030598A5087073139 @default.
• W3092030598 hasAuthorship W3092030598A5087998175 @default.
• W3092030598 hasAuthorship W3092030598A5090025679 @default.
• W3092030598 hasAuthorship W3092030598A5091833738 @default.
• W3092030598 hasBestOaLocation W30920305981 @default.
• W3092030598 hasConcept C126322002 @default.
• W3092030598 hasConcept C127413603 @default.
• W3092030598 hasConcept C164705383 @default.
• W3092030598 hasConcept C2776301958 @default.
• W3092030598 hasConcept C2778261982 @default.
• W3092030598 hasConcept C2778382381 @default.
• W3092030598 hasConcept C2778661090 @default.
• W3092030598 hasConcept C2778810321 @default.
• W3092030598 hasConcept C2779161974 @default.
• W3092030598 hasConcept C2780434524 @default.
• W3092030598 hasConcept C2780645631 @default.
• W3092030598 hasConcept C42219234 @default.
• W3092030598 hasConcept C71924100 @default.
• W3092030598 hasConcept C78519656 @default.
• W3092030598 hasConceptScore W3092030598C126322002 @default.
• W3092030598 hasConceptScore W3092030598C127413603 @default.
• W3092030598 hasConceptScore W3092030598C164705383 @default.
• W3092030598 hasConceptScore W3092030598C2776301958 @default.
• W3092030598 hasConceptScore W3092030598C2778261982 @default.
• W3092030598 hasConceptScore W3092030598C2778382381 @default.

• next